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Infusions and decoctions of Cymbopogon ambiguus have been used traditionally in Australia for
the treatment of headache, chest infections and muscle cramps. The aim of the present study
was to screen and identify bioactive compounds from C. ambiguus that could explain this
plant’s anti-headache activity. A dichloromethane extract of C. ambiguus was identified
as having activity in adenosine-diphosphate-induced human platelet aggregation and
serotonin-release inhibition bioassays. Subsequent fractionation of this extract led to the isola-
tion of four phenylpropenoids, eugenol, elemicin, eugenol methylether and trans-isoelemicin.
While both eugenol and elemicin exhibited dose-dependent inhibition of ADP-induced human
platelet serotonin release, only eugenol displayed potent inhibitory activity with an IC50 value
of 46.6mM, in comparison to aspirin, with an IC50 value of 46.1 mM. These findings provide
evidence to support the therapeutic efficacy of C. ambiguus in the non-conventional treatment
of headache and inflammatory conditions.
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Introduction
The native Australian lemongrass species, Cymbopogon
ambiguus A. Camus. (Poaceae) is a strongly aromatic
perennial grass found on rocky hillsides throughout the
Northern Territory of Australia (1). The leaves have been
used traditionally to treat chest infections, sores, muscle
cramps as well as headache and associated complaints
(infusions and decoctions) (1–3). Interestingly, a study
on Australian medicinal plants identified very
weak anti-viral (Ross River Virus) activity in a leaf
extract of C. ambiguus (4), while another study found
no anti-bacterial activity in extracts of Australian
C. ambiguus against four Gram-positive and four
Gram-negative bacterial species (5). Little is known
about the chemical constituents present in C. ambiguus
apart from a GC-MS study by Barr et al. (3), which
identified camphene, borneol, limonene, a-pinene,
a-terpineol, camphor, isoborneol, 4-terpineol, myrcene,
b-ocimene as being present in the essential oil. Nothing
has been reported to date in relation to substantiating its
use as a non-conventional traditional remedy for head-
ache, apart from our original report showing that
dichloromethane (DCM) (more potent extract) and
methanolic (MeOH) extracts displayed potent inhibition
of human platelet aggregation and serotonin (5-HT,
5-hydroxytryptamine) release (6). To further investigate
the basis for use of C. ambiguus as a remedy for head-
ache, we report here the isolation and identification of
principal bioactive constituents causing inhibition of
human platelet aggregation and serotonin (5-HT) release.
Cymbopogon ambiguus is a headache remedy used in
Australian traditional medicine for generalized headache
disorders. Headaches associated with nausea, such as
migraine are complex disorders, with abnormalities in
platelet function reported. Altered 5-HT transport,
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decreased platelet 5-HT content, altered platelet cytosolic
free-calcium concentrations and varying sensitivity to
platelet agonists such as adenosine diphosphate (ADP)
and collagen have been reported in association with head-
ache/migraine episodes (7–14). The serotonergic system is
thus thought to play an important role in the pathophysi-
ology of these disorders (15–20). We and others have
previously reported on the use of platelets as a model
to assess the therapeutic serotonergic potential of tested
chemicals in relation to potential headache/migraine
treatment (6,21,22).
Cymbopogon ambiguus has been used as a traditional
Australian aboriginal headache treatment and our studies
have shown that it displays potent anti-platelet activity.
To identify the bioactive constituent(s) responsible
for this activity, lemongrass leaves were sequentially
extracted with DCM then MeOH. Fractionation of the
DCM extract led to the identification of four phenylpro-
penoids as the principal constituents. We describe herein
the isolation and purification of these four phenylprope-
noids from C. ambiguus along with pharmacological
evaluation of two of these compounds. This is the first
report identifying specific constituents that underpin the
use of C. ambiguus as a non-conventional traditional
Australian anti-headache medicine.
Methods
Plant Collection
Cymbopogon ambiguus (whole plant) was collected in
1998 in the vicinity of Alice Springs, Northern
Territory, Australia. Identity of the material was con-
firmed by the Alice Springs Herbarium, with voucher
specimens deposited at the Herbarium and also in the
Genomics Research Centre, Gold Coast campus,
Griffith University (sample ID: DN3081).
Extraction and Isolation
Dried whole plants (283 g) of C. ambiguus were powdered
and exhaustively extracted (vigorous stirring in 2.5 l of
solvent for 3 h at 22C, then procedure repeated) with
DCM followed by MeOH at room temperature The
DCM extract was then concentrated and dried under
reduced pressure (50mmHg, 30C) to give a dark
green aromatic solid residue (7.53 g) and the residue
loaded onto a normal phase chromatography column
(silica gel, 150 g, Merck, 60 mm, 4.3 11.7 cm). The
column was then eluted by passing 600ml volume
through the column from 10% hexane in chloroform,
to 100% hexane in 10% increments. Fractions eluted
with 50% and 60% hexane were both found to exhibit
significant inhibition of ADP-induced platelet [14C]5-HT
release. Analytical HPLC [LunaTM C18, 5 mm analytical,
4.6mm 250mm, photo-diode-array (PDA) detection at
270 nm, 1.0mlmin1, method: 25–35% acetonitrile/H2O
gradient over 10min, followed by an increase to 45%
acetonitrile over a further 50min] of these fractions
indicated five common constituents, which were sepa-
rated by semi-preparative HPLC [LunaTM C18, 5 mm,
10mm 250mm, PDA, 4.5mlmin1, method as above]
to give the known compounds: eugenol (4-allyl-2-
methoxyphenol) (1) (75.4mg, 0.02% w/w); elemicin
(5-allyl-1,2,3-trimethoxybenzene) (2) (520mg, 0.18% w/
w); eugenol methylether (4-allyl-1,2-dimethoxybenzene)
(3) (322mg, 0.11% w/w); and trans iso-elemicin
(4) (1,2,3-trimethoxy-5-(1-propenyl) benzene) (162mg,
0.06 % w/w) (Fig. 3).
Chemicals and Solvents
ADP, acetyl salicylic acid (ASA or aspirin), dimethyl sulf-
oxide (DMSO) and deuterated chloroform (CDCl3) were
all obtained from Sigma chemical company (St Louis,
USA). 14C-5-hydroxytryptamine (14C-5-HT) (Amersham,
specific activity 57mCimmol1, 50 mCi ml1). All solvents
used were of HPLC grade, including acetonitrile
(CH3CN) (omnisolv. EM Science, Merck), chloroform
(CHCl3) (chromasolv. Riedel-de Haen), DCM (chromo-
solv. Riedel-de Haen), ethyl acetate (Banksia Scientific
Co. Pty. Ltd.), hexane (Mallinckrodt chromAR

HPLC)
and methanol (Omnisolv, EM Science, Merck).
Characterization of Isolated Compounds
Structural characterization of the four phenylpropenoids
was achieved by mass spectrometry (MS) (Bruker
Daltonics BioAPEX 47e), extensive NMR experiments
(Bruker AC-300, Karlsruhe, Germany) (1H, 1H-1H
COSY, 1H-13C HMBC, JMOD) and comparison of 1H
NMR (300MHz, CDCl3) data (see below) with previous-
ly reported assignments. Eugenol (1) (23): 1H NMR 
3.33 (d, 2H, 3J=6.7Hz, CH2); 3.88 (s, 3H, OCH3);
5.06 (dd, 1H, 2J=2Hz, 3Jcis=10Hz, HCHCHCH2);
5.07 (dd, 1H, 2J=2Hz, 3Jtrans=17Hz, HCHCHCH2);
5.50 (OH); 5.93 (ddd, 1H, 3Jcis=10Hz,
3Jtrans=17Hz,
3J=6.7Hz, HCHCHCH2); 6.67–6.72 (m, 2H, CCH
CHC(OH), CCHC(OCH3)); 6.86 (dd, 1H, Jortho=
8.5Hz, Jmeta=4.2Hz, CCHCHC(OH). MS calculated
for C10H13O2 [M+H]
+: 165.08. Found: 164.08.
Elemicin (2) (24): 1H NMR  3.33 (d, 2H, 3J=6.6Hz,
CH2); 3.82 (s, 3H, OCH3); 3.84 (s, 6H, (H3CO)CC
(OCH3)C(OCH3); 5.08 (dd, 1H,
2J=1.8Hz, 3Jcis=
10Hz, HCHCHCH2); 5.11 (dd, 1H,
2J=1.8Hz,
3Jtrans=17Hz, HCHCHCH2); 5.95 (ddd, 1H,
3Jcis=
10Hz, 3Jtrans=17Hz,
3J=6.6Hz, HCHCHCH2); 6.40
(s, 2H, 2 aromatic H). MS calculated for C12H16O3Na
[M+Na]+: 231.11. Found: 231.11. Eugenol methylether
(3) (23); 1H NMR  3.31 (d, 2H, 3J=6.6Hz,
HC=CH2); 3.84 (s, 3H, OCH3); 3.85 (s, 3H, OCH3);
5.04 (dd, 1H, 2J=1.5Hz, 3Jcis=10.1Hz, HCHCH
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CH2); 5.05 (dd, 1H,
2J=1.5Hz, 3Jtrans=16.8Hz, HCH
CHCH2); 5.95 (ddd, 1H,
3Jcis=10.1Hz,
3Jtrans=
16.8Hz, 3J=6.6Hz, HCHCHCH2); 6.75 (m, 3H,
3Jortho=8.4Hz,
4Jmeta=1.4Hz, 3 aromatic H). MS
calculated for C11H15O2 [M+H]
+: 179.09. Found:
179.09. trans-Isoelemicin (4) (25); 1H NMR  1.86 (dd,
3H, 3J=6.4Hz, 4J=1.5 HCCH3); 3.81 (s, 3H, OCH3);
3.83 (s, 6H, 2 x OCH3); 6.13 (dq, 1H,
3Jtrans=15.6Hz,
3J=6.4Hz, HCHCHCH2); 6.31 (dd, 1H,
4J=1.5Hz,
3Jtrans=15.6Hz, HCCHCH3); 6.54 (s, 2H, 2 aromatic
H). MS calculated for C12H17O3 [M+H]
+: 209.11.
Found: 209.11.
Platelet Aggregation and [14C]-5HT Release Bioassays
The bioassays utilised are based on a modified published
method, described previously by our group (26) and by
Groenewegen and Heptinstall (27). Fresh blood (45ml)
was collected from healthy human volunteers (20- to
35-year old, not taking aspirin or other drugs likely to
interfere with platelet function for at least 2 weeks prior
to blood sampling). Platelet aggregation and 5-HT release
were measured simultaneously. [14C]5-HT (6 ml) (specific
activity 50 mCi ml1) was added to 9ml of citrated blood
to label intracellular storage granules. Platelet-poor
plasma (PPP) and platelet-rich plasma (PRP) fractions
were prepared, with the PRP being adjusted to
300 109 platelets/l by dilution with PPP. A sample con-
sisting of 450 mL of PPP and 100 mL of either, PBS with
1% ethanol or DMSO (control), or the test sample, was
initially measured in order to set 100% aggregation (a
decrease in optical density reflects an increase in platelet
aggregation). The final concentration of ethanol or
DMSO did not exceed 0.2% (v/v). Labeled PRP
(450ml) was then stirred (1000 r.p.m. at 37C) for 3min
in the presence of 100 ml of the C. ambiguus extract (or
isolated compound) or PBS containing either 1% ethanol
or DMSO (control). ADP (50 ml) was then added to sam-
ples, and platelet aggregation was monitored for 6min-
utes. Platelet aggregation was measured in a four-channel
platelet aggregometer (Monitor IV plus, Helena
Laboratories, Beaumont, USA). Samples of PRP were
incubated without the addition of ADP to measure the
amount of [14C] 5-HT that was not taken up by platelets,
and which may have been spontaneously released during
the procedure (blank). ASA (50ml, 14mM) was then
added to irreversibly inhibit further 5-HT release, and
samples were placed on ice for 5min. Samples were
then centrifuged (6000 r.p.m.) for 8min, and duplicate
50 ml aliquots were taken from the supernatant and
counted (Wallac 1450, MicroBeta counter) for determi-
nation of % [14C] 5-HT release. Percentage 5-HT release
was calculated as follows:
Amount of 14C
 
5HT blank
Total counts blank  100%
IC50 values were generated using the software of
Graphpad prism (3.0).
Bioethics Clearance
Blood samples for the platelet studies were collected by a
qualified phlebotomist and the study had full ethical
clearance from the Griffith University Ethics Committee
for experimentation on human subjects. Informed written
consent was obtained from all participants.
Statistical Analysis
Platelet aggregation and 5-HT release response, was
expressed as a percentage of the control value. IC50
values (concentration producing 50% inhibition of the
maximum response) were calculated by non-linear regres-
sion analysis of the dose-response curves using the soft-
ware of Graphpad Prism (3.0). Results are presented as
the means SEM of n experiments.
Results
Extraction
Both DCM and MeOH extracts of C. ambiguus produced
a dark green residue that was strongly aromatic (lemon
scented). The total weight of the DCM extract after
drying was 7.53 g, and for the MeOH extract, 16.84 g.
Isolation and Structural Characterization
Silica column chromatography (10% gradient increments
from 10:90 hexane:CHCl3 through to 100:0 hexane:
CHCl3 elution) of the DCM fraction eluted an active
50:50–60:40 hexane fraction. The dried residue (weighing
1.16 g) was resuspended in CH3CN and fractionation of
the soluble components utilising HPLC, afforded five
compounds (Figs 1 and 2). Four of these compounds
were purified further (purity was ascertained by HPLC
analysis) and then subjected to MS and NMR analysis.
The fifth compound (eluting at 54.11min) (Fig. 2) was
not successfully purified and was therefore not structur-
ally characterised in these studies.
The assignment of the structures for eugenol, elemicin,
eugenol methylether and trans-iso-elemicin (Fig. 3), which
are known compounds, was established on the basis of
the 1H NMR and MS data. Chemical shifts were identi-
cal to those previously reported (see Methods section—
Characterization of isolated compounds). The chemical
structure and identity of each compound is shown in
Fig. 3. The isolation of these compounds was guided by
the activity of the active hexane fraction (50% and 60%)
in the ADP-induced platelet 5-HT release bioassay. Both
eugenol and elemicin were investigated pharmacologically
in further studies.
eCAM 2009 3 of 8
 at Consolidation Plus (GRGCA) on April 5, 2010 
http://ecam
.oxfordjournals.org
D
ow
nloaded from
 
Figure 1. Bioassay-guided fractionation of C. ambiguus (whole plant) to isolate compounds (14).
Figure 2. HPLC chromatogram of the combined 50:50 and 60:40 hexane/CHCl3 fractions: eugenol (33.8min); elemicin (49.1min); eugenol methy-
lether (50.7min); trans-iso-elemicin (53.3min).
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Platelet Aggregation and [14C]-5HT Release Bioassay
For the platelet aggregation and 5-HT release studies, a
submaximal concentration of ADP was used to stimulate
the platelet response. Elemicin’s affect on inhibiting
ADP-induced platelet aggregation was less potent than
eugenol in our results and therefore we focussed our
interests on eugenol. Effects of increasing eugenol con-
centrations (0, 46, 61 and 152 mM) on the ADP-induced
platelet aggregation clearly showed that concentrations
above 61 mM did not inhibit platelet aggregation
further. Interestingly, eugenol and elemicin exhibited
dose-dependent inhibition of ADP (2 mM)-induced plate-
let 5-HT release, although eugenol at a much lower con-
centration than elemicin [see Table 1 and Fig. 4 (eugenol
data only)]. Concentration ranges of eugenol, elemicin
and aspirin chosen to examine their inhibitory activity
on human platelet 5-HT release were 2.8 10 6 to
2.8 104M, 1.7 104 to 3.5 103 and 2.5 106 to
2.5 104M, respectively. Despite structural similarities,
there were remarkable differences in the level of activity
between eugenol and elemicin (Table 1). Eugenol was up
to 50 times more potent than elemicin, with IC50 values
calculated to be 46.6 mM and 1729.8 mM, respectively.
ASA is an irreversible inhibitor of platelet cyclooxygenase
(COX) activity, and still remains the standard to which
other anti-platelet drugs are often compared (28). The
dose-dependent effect of eugenol compared favorably to
ASA (Fig. 4), which exhibited an IC50 value of 46.1 mM
in these studies.
Discussion
Bioassay-directed fractionation of the DCM extract of C.
ambiguus afforded the isolation and structural character-
ization of four compounds, eugenol, elemicin, eugenol
methylether and trans-iso-elemicin. Like 1,8-cineole
(the major active constituent of Melaleuca, Eucalyptus
and Prostanthera sp.), eugenol and elemicin are vola-
tile monoterpenoids (i.e. C10 compounds) with anti-
inflammatory affects (29). Indeed, other similar com-
pounds have previously been isolated from Cymbopogon
sp. including, limonene and a-terpineol, which are gener-
ally common components of citrus oils (30,31). Eugenol
and elemicin have also been isolated from several other
plants including Myristica fragrans (nutmeg) and
Syzygium aromaticum (clove oil), where they are believed
to be some of the major constituents responsible for the
biological activities of these plants (29,32,33). Elemicin
has been identified previously in another Australian
native, Cymbopogon procerus (3); however, this is the
first report of eugenol in the Cymbopogon sp. and
indeed the first evidence for the presence of these com-
pounds in the Australian native lemongrass species,
C. ambiguus.
In these studies, eugenol was found to be up to 50-fold
more active than elemicin at inhibiting 5-HT release from
human platelets. From dose-dependant responses IC50
values of 46.6 mM and 1729.8 mM were determined,
respectively, in our 5-HT release inhibition assay (Fig. 4
and Table 1). In previous studies using rabbit platelets,
eugenol was found to be up to 1000 times more potent
than elemicin and was found to compare favorably with
indomethacin (34). An additional study found eugenol to
be 29 times more potent than aspirin at inhibiting ara-
chidonic acid-induced human platelet aggregation (35).
Based on reports in the literature and the structural
characteristics of eugenol methylether and trans-
iso-elemicin, which were also isolated in the active frac-
tion, these two compounds were not investigated further
in our pharmacological studies (34). Although, interest-
ingly it has been demonstrated that eugenol methylether
has anti-nociceptive effects on formalin-induced hyper-
algesia (36). However, our interests and discussion here
focus on eugenol due to its principal activity in our
bioassays.
Studies have demonstrated that eugenol has anti-
oxidant, anti-inflammatory, anti-platelet (using rabbit
platelets), anti-nociceptive and anti-ulcerogenic effects
(37–42). Furthermore, this drug has also been shown to
potentiate GABAA transmission (43,44). Eugenol is
Figure 3. Structure of the four phenylpropenoides [eugenol (4-allyl-2-methoxyphenol) (1); elemicin (5-allyl-1,2,3-trimethoxybenzene) (2); eugenol
methylether (4-allyl-1,2-dimethoxybenzene) (3) and trans iso-elemicin (1,2,3-trimethoxy-5-(1-propenyl) benzene) (4)] isolated from the Australian
native lemongrass species C. ambiguus.
Table 1. IC50 values for components of C. ambiguus and aspirin against
ADP-induced platelet 5-HT release
Compound IC50 (mM)
Eugenol 46.6 3.7
Elemicin 1729.8 147.5
Acetylsalicylic acid (ASA, Aspirin) 46.1 3.1
Results represent IC50SEM (n=4) as determined by the software of
Graphpad prism (3.0).
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reported to cause inhibition of thromboxane A2 and B2
formation, without any influence on the lipoxygenase
pathway and appears to be an inhibitor of COX activity
similarly to aspirin. In addition, more recent data
indicates that this drug inhibits the rise in intracellular
Ca2+ caused by collagen, adrenalin, ADP and AA (38).
Hence, eugenol appears to have pharmaceutical features
that might be considered ideal characteristics of a
migraine treatment. In support of these earlier studies
(29), our results provide evidence that eugenol does not
have significant effects on the primary phase of ADP
induced platelet aggregation. Concentrations of eugenol
above 61 mM did not inhibit platelet aggregation further
(Fig. 5) and this result strongly suggests that eugenol
selectively targets the second phase of platelet aggrega-
tion. This second phase of aggregation involves the ‘re-
lease reaction’, which is dependent on cytosolic increases
in Ca2+ and the activation of PLC (phospolipase C) and
the COX pathway (45), which mediate platelet dense
granule secretion. Therefore, 5-HT release could be com-
pletely inhibited even when aggregation is not. In line
with this, high concentrations of eugenol that inhibited
5-HT release only inhibited the second phase of platelet
aggregation (Figs 4 and 5). The modulation of 5-HT
release was the principal pathway we were interested in
investigating.
Aspirin is a potent anti-inflammatory analgesic, known
to cause inhibition of the COX pathway, namely the
COX-1 and COX-2 isoforms of this enzyme. In general,
aspirin is used to assist in prevention of heart attacks,
strokes, arthritis, diabetes and migraines and may also
slow the mental decline of old age or provide neuropro-
tection in a mouse model of Parkinson’s disease (46,47).
Previous studies have also shown that a single concentra-
tion of eugenol, inhibits both COX-1 and COX-2
enzymes (48). Our results show that eugenol exhibits
pharmacological effects that resemble those of aspirin
and this data supports previous evidence that eugenol is
a COX inhibitor and acts as a potent anti-platelet drug.
Interestingly, eugenol is reported to exhibit analgesic
properties (38) and has also been used to treat gastro-
intestinal upsets and chronic diarrhoea and is approved
by the Food and Drug Administration of the USA. It is
noteworthy that other traditional medicines known to
modulate 5-HT activity have also been reported as treat-
ments for gastrointestinal tract (49) and allergenic dis-
orders (50). Eugenol is also likely to have potential in
the treatment of other diseases related to platelet aggre-
gation, such as, thrombosis, transient ischemia,
Figure 4. Dose-dependent inhibition of ADP (2 mM)-induced human platelet [14C]5-HT release. Results represent the mean of duplicate analyses
performed on PRP obtained from four different individuals.
Figure 5. Platelet aggregation trace showing an example of the effect of
low to high doses (0, 46, 61 and 152 mM) of eugenol on ADP-induced
platelet aggregation. The change in light transmission is represented as
percentage of platelet aggregation using a four-channel platelet aggreg-
ometer. Results are duplicates obtained from PRP from two different
individuals.
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inflammation, tumor growth and promotion of athero-
sclerosis (51,52). However, there is only limited data
relating to its potential use as an anti-headache/migraine
or anti-platelet drug (29). Few side effects have been
reported in relation to the use of eugenol. One report
on its use as a traditional dental material does however
document local irritative and cytotoxic effects along with
hypersensitivity reactions when used in contact with soft
oral tissues (53).
Conclusions
In conclusion, four known compounds (eugenol, elemi-
cin, eugenol methyl ether and trans-isoelemicin) were iso-
lated from the DCM extract of C. ambiguus. Eugenol and
elemicin were identified as contributing the principal
activity of this extract and demonstrated dose-dependent
inhibition of ADP-induced human platelet [14C]5-HT
release, with IC50 values of 46.6mM and 1729.8 mM,
respectively. Eugenol was also identified as having
potent affects on the second-phase of platelet activation.
The results of these studies provide evidence identifying
specific constituents (principally eugenol) that have anti-
platelet activity (Fig. 6) that establish the basis of the
therapeutic activity and traditional use of C. ambiguus
as a non-conventional remedy for headache conditions.
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